HOST IMMUNE PROFILING IN PATIENTS WITH SEVERE COVID-19: BIOMARKERS OF IMMUNE DYSREGULATION
Downloads
Objective: Host immune profiling in severe cases of COVID-19 is an important area of focus that seeks to explain the immune dysregulation mechanisms impacting upon health. This study examines the immune landscape of patients suffering from severe COVID-19 in detail, mapping specific biomarkers of immune dysfunction. Method: By harnessing advanced technologies, including flow cytometry and transcriptomic analysis, this study captures the dynamic changes within immune cell subsets and their related pathways. Central to this exploration is understanding the interplay between innate and adaptive immunity in the context of severe COVID-19 infections. Results: Through comprehensive analysis, the study delineates the aberrant immune responses infiltrated by SARS-CoV-2, characterized by hyper inflammation, cytokine storm phenomena, and substantial variations in immunological profiles. Detailed profiling reveals notable deviations in neutrophil counts, lymphopenia, and altered cytokine levels. These disruptions are instrumental in the cascading complexities observed during disease progression. Consequently, the research identifies potential targets for modulation and future clinical application, thus aiming to enhance recovery rates and curtail mortality linked to severe COVID-19. Novelty: The identification of unique biomarkers offers profound insights into pathogenic processes, presenting opportunities for targeted therapeutic interventions and improved prognostic evaluations. The research posits that a strategic approach toward host immune profiling can profoundly impact the management and understanding of COVID-19. The findings underscore the necessity for precision medicine tailored to inherent immune irregularities, advocating for the integration of identified biomarkers in clinical practices to mitigate severe disease outcomes. The study contributes to existing literature by advocating for a paradigm shift, where immune profiling informs the design of bespoke therapeutic strategies and paves the way for innovative research trajectories in combating pandemic-related challenges.
Y. D. Gao et al., “Risk factors for severe and critically ill COVID‐19 patients: a review,” Allergy, vol. 76, no. 2, pp. 428–455, 2021, [Online]. Available: https://onlinelibrary.wiley.com/doi/10.1111/all.14657
F. J. Ryan et al., “Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection,” BMC Med., vol. 20, pp. 1–23, 2022, [Online]. Available: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-022-02286-9
P. Brodin, “Immune determinants of COVID-19 disease presentation and severity,” Nat. Med., 2021, [Online]. Available: https://www.nature.com/articles/s41591-020-01202-8
A. Bodaghi, N. Fattahi, and A. Ramazani, “Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases,” Heliyon, 2023, [Online]. Available: https://www.cell.com/heliyon/fulltext/S2405-8440(23)00105-3
A. Baghela et al., “Predicting sepsis severity at first clinical presentation: The role of endotypes and mechanistic signatures,” EBioMedicine, vol. 75, 2022, [Online]. Available: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00554-1/fulltext
W. G. Land, “Role of DAMPs in respiratory virus-induced acute respiratory distress syndrome—with a preliminary reference to SARS-CoV-2 pneumonia,” Genes Immun., 2021, [Online]. Available: https://www.nature.com/articles/s41435-021-00137-6
U. Ranga, “SARS-CoV-2 aerosol and droplets: an overview,” VirusDisease, 2021, [Online]. Available: https://link.springer.com/article/10.1007/s13337-021-00662-3
G. Costagliola, E. Spada, and R. Consolini, “Age‐related differences in the immune response could contribute to determine the spectrum of severity of COVID‐19,” Immunity, Inflamm. Dis., vol. 9, no. 2, pp. 331–339, 2021, [Online]. Available: https://onlinelibrary.wiley.com/doi/10.1002/iid3.403
B. Hu, S. Huang, and L. Yin, “The cytokine storm and COVID‐19,” J. Med. Virol., 2021, [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267170/
M. S. Diamond and T. D. Kanneganti, “Innate immunity: the first line of defense against SARS-CoV-2,” Nat. Immunol., 2022, [Online]. Available: https://www.nature.com/articles/s41590-021-01091-0
A. Kałużna, P. Olczyk, and K. Komosińska-Vassev, “The role of innate and adaptive immune cells in the pathogenesis and development of the inflammatory response in ulcerative colitis,” J. Clin. Med., 2022, [Online]. Available: https://www.mdpi.com/2077-0383/11/12/3404
M. S. Abers et al., “An immune-based biomarker signature is associated with mortality in COVID-19 patients,” JCI Insight, vol. 6, no. 1, p. e144455, 2021, [Online]. Available: https://insight.jci.org/articles/view/144455
B. M. Liu, T. B. Martins, L. K. Peterson, and H. R. Hill, “Clinical significance of measuring serum cytokine levels as inflammatory biomarkers in adult and pediatric COVID-19 cases: A review,” Cytokine, 2021, [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473022/
M. Kubánková et al., “Physical phenotype of blood cells is altered in COVID-19,” Biophys. J., vol. 120, no. 14, pp. 2838–2847, 2021, [Online]. Available: https://www.cell.com/biophysj/fulltext/S0006-3495(21)00441-6
S. Aggarwal, A. Acharjee, A. Mukherjee, M. S. Baker, and S. Srivastava, “Role of multiomics data to understand host–pathogen interactions in COVID-19 pathogenesis,” J. Proteome Res., vol. 20, no. 2, pp. 1107–1132, 2021, [Online]. Available: https://pubs.acs.org/doi/10.1021/acs.jproteome.0c00917
B. Shibru et al., “Detection of immune checkpoint receptors–a current challenge in clinical flow cytometry,” Front. Immunol., vol. 12, p. 694055, 2021, [Online]. Available: https://www.frontiersin.org/articles/10.3389/fimmu.2021.694055/full
L. P. Arnett et al., “Reagents for mass cytometry,” Chem. Rev., vol. 123, no. 3, pp. 1166–1205, 2023, [Online]. Available: https://pubs.acs.org/doi/10.1021/acs.chemrev.2c00401
C. E. Burnett et al., “Mass cytometry reveals a conserved immune trajectory of recovery in hospitalized COVID-19 patients,” Immunity, vol. 55, no. 7, pp. 1284–1298, 2022, [Online]. Available: https://www.cell.com/immunity/fulltext/S1074-7613(22)00317-5
K. A. Jagadeesh et al., “Identifying disease-critical cell types and cellular processes by integrating single-cell RNA-sequencing and human genetics,” Nat. Genet., vol. 54, no. 10, pp. 1479–1492, 2022, [Online]. Available: https://www.nature.com/articles/s41588-022-01179-8
S. Varchetta et al., “Unique immunological profile in patients with COVID-19,” Cell. Mol. Immunol., vol. 18, no. 3, pp. 604–612, 2021, [Online]. Available: https://www.nature.com/articles/s41423-020-00595-7
M. Jamal et al., “Immune dysregulation and system pathology in COVID-19,” Virulence, vol. 12, no. 1, pp. 918–936, 2021, [Online]. Available: https://www.tandfonline.com/doi/full/10.1080/21505594.2021.1916411
M. C. Jaimes, M. Leipold, G. Kraker, E. A. Amir, H. Maecker, and J. Lannigan, “Full spectrum flow cytometry and mass cytometry: A 32‐marker panel comparison,” Cytom. Part A, vol. 101, no. 11, pp. 942–959, 2022, [Online]. Available: https://onlinelibrary.wiley.com/doi/10.1002/cyto.a.24562
L. Y. R. Wong and S. Perlman, “Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses—are we our own worst enemy?,” Nat. Rev. Immunol., 2022, [Online]. Available: https://www.nature.com/articles/s41577-021-00656-2
L. Huang et al., “Dynamic blood single-cell immune responses in patients with COVID-19,” Signal Transduct. Target. Ther., vol. 6, no. 1, p. 110, 2021, [Online]. Available: https://www.nature.com/articles/s41392-021-00531-3
A. Kusnadi et al., “Severely ill patients with COVID-19 display impaired exhaustion features in SARS-CoV-2–reactive CD8+ T cells,” Sci. Immunol., vol. 6, no. 55, p. eabe4782, 2021, [Online]. Available: https://www.science.org/doi/10.1126/sciimmunol.abe4782
A. A. Rabaan et al., “Role of inflammatory cytokines in COVID-19 patients: a review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to counter cytokine storm,” Vaccines, vol. 9, no. 5, p. 436, 2021, [Online]. Available: https://www.mdpi.com/2076-393X/9/5/436
M. S. Rha and E. C. Shin, “Activation or exhaustion of CD8+ T cells in patients with COVID-19,” Cell. Mol. Immunol., 2021, [Online]. Available: https://www.nature.com/articles/s41423-020-00562-2
H. A. Shuwa et al., “Alterations in T and B cell function persist in convalescent COVID-19 patients,” Med, vol. 2, no. 6, pp. 720–735, 2021, [Online]. Available: https://www.cell.com/med/fulltext/S2666-6340(21)00147-9
J. L. Yates et al., “Serological analysis reveals an imbalanced IgG subclass composition associated with COVID-19 disease severity,” Cell Reports Med., vol. 2, no. 7, 2021, [Online]. Available: https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00212-1
T. W. Leulseged et al., “Laboratory biomarkers of COVID-19 disease severity and outcome: Findings from a developing country,” PLoS One, vol. 16, no. 3, p. e0246087, 2021, [Online]. Available: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0246087
S. P. Kubli, T. Berger, D. V Araujo, L. L. Siu, and T. W. Mak, “Beyond immune checkpoint blockade: emerging immunological strategies,” Nat. Rev. Drug Discov., vol. 20, no. 12, pp. 899–919, 2021, [Online]. Available: https://www.nature.com/articles/s41573-021-00226-0
W. Jiang et al., “Exhausted CD8+ T cells in the tumor immune microenvironment: new pathways to therapy,” Front. Immunol., vol. 11, p. 622509, 2021, [Online]. Available: https://www.frontiersin.org/articles/10.3389/fimmu.2020.622509/full
S. Kaur et al., “The looming storm: blood and cytokines in COVID-19,” Blood Rev., vol. 46, p. 100743, 2021, [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355567/
M. Milenkovic et al., “D‐dimer, CRP, PCT, and IL‐6 levels at admission to ICU can predict in‐hospital mortality in patients with COVID‐19 pneumonia,” Oxid. Med. Cell. Longev., vol. 2022, no. 1, p. 8997709, 2022, [Online]. Available: https://www.hindawi.com/journals/omcl/2022/8997709/
S. K. Byeon et al., “Development of a multiomics model for identification of predictive biomarkers for COVID-19 severity: a retrospective cohort study,” Lancet Digit. Heal., vol. 4, no. 9, pp. e632--e645, 2022, [Online]. Available: https://www.thelancet.com/journals/landig/article/PIIS2589-7500(22)00108-6/fulltext
C. Botta et al., “FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology,” Blood Adv., vol. 6, no. 2, pp. 690–703, 2022, [Online]. Available: https://ashpublications.org/bloodadvances/article/6/2/690/476395/FlowCT-for-the-analysis-of-large
B. Vijayakumar et al., “Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease,” Immunity, vol. 55, no. 3, pp. 542–556, 2022, [Online]. Available: https://www.cell.com/immunity/fulltext/S1074-7613(22)00141-0
L. Y. Tan, T. V Komarasamy, and V. R. M. T. Balasubramaniam, “Hyperinflammatory immune response and COVID-19: a double edged sword,” Front. Immunol., vol. 12, p. 742941, 2021, [Online]. Available: https://www.frontiersin.org/articles/10.3389/fimmu.2021.742941/full
D. M. Santer et al., “Interferon-λ treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity,” Nat. Commun., vol. 13, no. 1, p. 6992, 2022, [Online]. Available: https://www.nature.com/articles/s41467-022-34627-2
M. Iannetta et al., “Baseline T-lymphocyte subset absolute counts can predict both outcome and severity in SARS-CoV-2 infected patients: a single center study,” Sci. Rep., vol. 11, no. 1, p. 12762, 2021, [Online]. Available: https://www.nature.com/articles/s41598-021-92211-1
M. Rudiansyah et al., “Coronavirus disease 2019 (COVID‐19) update: From metabolic reprogramming to immunometabolism,” J. Med. Virol., vol. 94, no. 10, pp. 4611–4627, 2022, [Online]. Available: https://onlinelibrary.wiley.com/doi/10.1002/jmv.27829
B. Soskic et al., “Immune disease risk variants regulate gene expression dynamics during CD4+ T cell activation,” Nat. Genet., vol. 54, no. 6, pp. 817–826, 2022, [Online]. Available: https://www.nature.com/articles/s41588-022-01075-1
Y. Que et al., “Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality,” Int. Rev. Immunol., vol. 41, no. 2, pp. 217–230, 2022, [Online]. Available: https://www.tandfonline.com/doi/full/10.1080/08830185.2021.1916887
T. P. Velavan et al., “Host genetic factors determining COVID-19 susceptibility and severity,” EBioMedicine, vol. 72, 2021, [Online]. Available: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00096-4/fulltext
Copyright (c) 2025 Mustafa Kareem AL-Azzawi, Husam Fadhil Hasan, Mojtaba Qati Dahdoh, Hayder Mohsin Ali
This work is licensed under a Creative Commons Attribution 4.0 International License.
